Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (the Company), a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies, has announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a price to the public of US$5 per share (the Offering). In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. All of the securities are being offered by the Company. The Offering is expected to close on November 9, 2026, subject to customary closing conditions.
Latham & Watkins LLP advised the underwriters in the offering with a Capital Markets team led by New York partner Nathan Ajiashvili, with associates Kathleen Mehary, Yulong Li, and Renyang Gao.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
